Serum NfL levels were strongly correlated between the two technologies in MS patients (Spearman r = 0.86, 95% CI [0.821‐0.895]) (Figure 1B) and in HCs (Spearman r = 0.76, 95%CI [0.533‐0.882], Supplementary Figure B). This evidence concerns the gene NEFL and myeloid sarcoma.